Tezepelumab · Tezspire, MEDI-9929

What is Tezepelumab?

Tezepelumab-ekko is a human monoclonal antibody (IgG2λ) that binds thymic stromal lymphopoietin (TSLP) and blocks its interaction with the TSLP receptor. TSLP is an upstream cytokine in inflammatory cascades.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Tezspire, MEDI-9929, AMG-157, MEDI-19929

Drug type

Monoclonal antibody

Targets

thymic stromal lymphopoietin (TSLP)

Mechanism

Antagonist of thymic stromal lymphopoietin (TSLP)

Pathways

airway inflammation, mucosal inflammation, eosinophil reduction, IgE reduction

Therapy area

Respiratory

Developer

Astrazeneca Ab

In trials of

AMGN

FDA status

Approved as Tezspire (December 17, 2021), BLA761224 · FDA label

UNII

RJ1IW3B4QX

✅ FDA-approved uses

• Severe asthma
• Chronic rhinosinusitis with nasal polyps

From the indications section of the FDA label (version of Oct 17, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Obstructive Pulmonary Disease (COPD)

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Tezspire (2025-10-17), indications
• ClinicalTrials.gov NCT06883305

Updated Oct 3, 2026.